Passage Bio Inc has a consensus price target of $7, established from looking at the 14 latest analyst ratings. The last 3 analyst ratings were released from Canaccord Genuity, Canaccord Genuity, and Raymond James on May 15, 2024, March 5, 2024, and November 14, 2023. With an average price target of $10.67 between Canaccord Genuity, Canaccord Genuity, and Raymond James, there's an implied 1036.08% upside for Passage Bio Inc from these 3 analyst ratings.
1calculated from analyst ratings
Buy Now | Get Alert | |||||||
---|---|---|---|---|---|---|---|---|
05/15/2024 | Buy Now | 1284.6% | Canaccord Genuity | Whitney Ijem | $14 → $13 | Maintains | Buy | Get Alert |
03/05/2024 | Buy Now | 1391.11% | Canaccord Genuity | Whitney Ijem | → $14 | Reiterates | Buy → Buy | Get Alert |
11/14/2023 | Buy Now | 432.54% | Raymond James | Danielle Brill | $9 → $5 | Maintains | Outperform | Get Alert |
08/08/2023 | Buy Now | 858.57% | Chardan Capital | Geulah Livshits | $11 → $9 | Maintains | Buy | Get Alert |
05/12/2023 | Buy Now | 858.57% | Raymond James | Danielle Brill | $10 → $9 | Maintains | Outperform | Get Alert |
12/15/2022 | Buy Now | 1071.58% | Chardan Capital | Geulah Livshits | $18 → $11 | Maintains | Buy | Get Alert |
11/11/2022 | Buy Now | 1071.58% | Guggenheim | Debjit Chattopadhyay | $13 → $11 | Maintains | Buy | Get Alert |
11/11/2022 | Buy Now | 432.54% | Citigroup | Neena Bitritto-Garg | $7 → $5 | Maintains | Buy | Get Alert |
11/08/2022 | Buy Now | 752.06% | Canaccord Genuity | Whitney Ijem | → $8 | Initiates | → Buy | Get Alert |
05/17/2022 | Buy Now | 965.08% | Citigroup | Neena Bitritto-Garg | $15 → $10 | Maintains | Buy | Get Alert |
05/17/2022 | Buy Now | 965.08% | Raymond James | Danielle Brill | $24 → $10 | Maintains | Outperform | Get Alert |
03/08/2022 | Buy Now | — | JP Morgan | Anupam Rama | — | Downgrade | Overweight → Neutral | Get Alert |
03/04/2022 | Buy Now | 2456.18% | Raymond James | Danielle Brill | $29 → $24 | Maintains | Outperform | Get Alert |
01/19/2022 | Buy Now | 539.05% | Goldman Sachs | Madhu Kumar | $29 → $6 | Downgrade | Buy → Neutral | Get Alert |
The latest price target for Passage Bio (NASDAQ:PASG) was reported by Canaccord Genuity on May 15, 2024. The analyst firm set a price target for $13.00 expecting PASG to rise to within 12 months (a possible 1284.60% upside). 4 analyst firms have reported ratings in the last year.
The latest analyst rating for Passage Bio (NASDAQ:PASG) was provided by Canaccord Genuity, and Passage Bio maintained their buy rating.
There is no last upgrade for Passage Bio
The last downgrade for Passage Bio Inc happened on March 8, 2022 when JP Morgan changed their price target from N/A to N/A for Passage Bio Inc.
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Passage Bio, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Passage Bio was filed on May 15, 2024 so you should expect the next rating to be made available sometime around May 15, 2025.
While ratings are subjective and will change, the latest Passage Bio (PASG) rating was a maintained with a price target of $14.00 to $13.00. The current price Passage Bio (PASG) is trading at is $0.94, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.